West Pharmaceutical Services, Inc. $WST Shares Sold by Rossby Financial LCC

Rossby Financial LCC decreased its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 11.6% in the 2nd quarter, HoldingsChannel reports. The firm owned 903 shares of the medical instruments supplier’s stock after selling 118 shares during the period. Rossby Financial LCC’s holdings in West Pharmaceutical Services were worth $198,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in West Pharmaceutical Services by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 9,231,721 shares of the medical instruments supplier’s stock valued at $2,066,798,000 after purchasing an additional 244,259 shares during the last quarter. Brown Advisory Inc. increased its stake in shares of West Pharmaceutical Services by 28.1% during the 1st quarter. Brown Advisory Inc. now owns 3,268,478 shares of the medical instruments supplier’s stock valued at $731,747,000 after acquiring an additional 716,442 shares during the last quarter. Durable Capital Partners LP increased its stake in shares of West Pharmaceutical Services by 146.8% during the 1st quarter. Durable Capital Partners LP now owns 1,573,119 shares of the medical instruments supplier’s stock valued at $352,190,000 after acquiring an additional 935,721 shares during the last quarter. APG Asset Management N.V. increased its stake in shares of West Pharmaceutical Services by 8.7% during the 1st quarter. APG Asset Management N.V. now owns 1,562,139 shares of the medical instruments supplier’s stock valued at $323,766,000 after acquiring an additional 124,737 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of West Pharmaceutical Services by 43.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,134,706 shares of the medical instruments supplier’s stock valued at $254,038,000 after acquiring an additional 343,997 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Analyst Ratings Changes

WST has been the subject of a number of research analyst reports. Evercore ISI upped their price objective on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “outperform” rating in a research note on Thursday, October 23rd. UBS Group upped their price objective on shares of West Pharmaceutical Services from $320.00 to $355.00 and gave the company a “buy” rating in a research note on Friday. KeyCorp upped their price objective on shares of West Pharmaceutical Services from $325.00 to $350.00 and gave the company an “overweight” rating in a research note on Friday, October 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Tuesday, October 14th. Finally, Zacks Research downgraded shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 23rd. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $349.11.

West Pharmaceutical Services Stock Down 1.3%

WST opened at $283.54 on Wednesday. The firm has a 50 day moving average price of $260.89 and a 200 day moving average price of $235.79. The company has a market cap of $20.40 billion, a PE ratio of 42.01, a price-to-earnings-growth ratio of 4.12 and a beta of 1.07. West Pharmaceutical Services, Inc. has a 1 year low of $187.43 and a 1 year high of $348.90. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.18 and a current ratio of 2.87.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.29. The firm had revenue of $804.60 million during the quarter, compared to the consensus estimate of $788.42 million. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The company’s revenue was up 7.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. Sell-side analysts expect that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.